Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Scanning cytometry with a LEAP: laser-enabled analysis and processing of live cells in situ.

Szaniszlo P, Rose WA, Wang N, Reece LM, Tsulaia TV, Hanania EG, Elferink CJ, Leary JF.

Cytometry A. 2006 Jul;69(7):641-51.

2.

Optoinjection for efficient targeted delivery of a broad range of compounds and macromolecules into diverse cell types.

Clark IB, Hanania EG, Stevens J, Gallina M, Fieck A, Brandes R, Palsson BO, Koller MR.

J Biomed Opt. 2006 Jan-Feb;11(1):014034.

PMID:
16526911
3.

Automated in situ measurement of cell-specific antibody secretion and laser-mediated purification for rapid cloning of highly-secreting producers.

Hanania EG, Fieck A, Stevens J, Bodzin LJ, Palsson BØ, Koller MR.

Biotechnol Bioeng. 2005 Sep 30;91(7):872-6.

PMID:
15937942
4.

High-throughput laser-mediated in situ cell purification with high purity and yield.

Koller MR, Hanania EG, Stevens J, Eisfeld TM, Sasaki GC, Fieck A, Palsson BØ.

Cytometry A. 2004 Oct;61(2):153-61.

5.

Addition of the human interferon beta scaffold attachment region to retroviral vector backbones increases the level of in vivo transgene expression among progeny of engrafted human hematopoietic stem cells.

Murray L, Travis M, Luens-Abitorabi K, Olsson K, Plavec I, Forestell S, Hanania EG, Hill B.

Hum Gene Ther. 2000 Sep 20;11(14):2039-50.

PMID:
11020802
6.

Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD).

Olsson K, Gerard CJ, Zehnder J, Jones C, Ramanathan R, Reading C, Hanania EG.

Leukemia. 1999 Nov;13(11):1833-42.

PMID:
10557059
7.

Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma.

Bachier CR, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Andreeff M, Cabanillas F, Champlin R, Choudhury R, Berenson R, Heimfeld S, Deisseroth AB.

Leuk Lymphoma. 1999 Jan;32(3-4):279-88.

PMID:
10037025
10.

Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy.

Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Deisseroth AB, et al.

Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15346-51. Erratum in: Proc Natl Acad Sci U S A 1997 May 13;94(10):5495.

11.

Regulation of retinoblastoma gene expression in a mouse mammary tumor model.

Hanania EG, Au WW, Ullrich RL, Papaconstantinou J.

Cancer Gene Ther. 1995 Dec;2(4):251-61.

PMID:
8548579
12.

Recent advances in the application of gene therapy to human disease.

Hanania EG, Kavanagh J, Hortobagyi G, Giles RE, Champlin R, Deisseroth AB.

Am J Med. 1995 Nov;99(5):537-52. Review.

PMID:
7485213
13.

Transduction of MDR1 into human and mouse haemopoietic progenitor cells: use of rhodamine (Rh123) to determine transduction frequency and in vivo selection.

Hegewisch-Becker S, Hanania EG, Fu S, Körbling M, Deisseroth AB, Andreeff M.

Br J Haematol. 1995 Aug;90(4):876-83.

PMID:
7669666
14.

PML/RARalpha, a fusion protein in acute promyelocytic leukemia, prevents growth factor withdrawal-induced apoptosis in TF-1 cells.

Fu S, Consoli U, Hanania EG, Zu Z, Claxton DF, Andreeff M, Deisseroth AB.

Clin Cancer Res. 1995 Jun;1(6):583-90.

15.

Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene.

Hanania EG, Fu S, Zu Z, Hegewisch-Becker S, Korbling M, Hester J, Durett A, Andreeff M, Mechetner E, Holzmayer T, et al.

Gene Ther. 1995 Jun;2(4):285-94.

PMID:
7552989
16.

Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit.

Hanania EG, Fu S, Roninson I, Zu Z, Deisseroth AB.

Gene Ther. 1995 Jun;2(4):279-84. Erratum in: Gene Ther 1995 Aug;2(6):433.

PMID:
7552988
18.

Genetic therapy using bone marrow transplantation.

Giles RE, Hanania EG, Fu S, Deisseroth A.

Cancer Treat Res. 1995;76:271-80. Review. No abstract available.

PMID:
7577339
19.

Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.

Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, et al.

Blood. 1994 May 15;83(10):3068-76.

21.

Molecular approaches to the diagnosis and treatment of cancer.

Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Hanania EG, Fu S, Randhawa GS, Cha Y, Fang X, et al.

Stem Cells. 1993 Oct;11 Suppl 3:129-30.

PMID:
7905320
22.

Genetic therapy of human neoplastic disease.

Deisseroth AB, Hanania EG, Fu S, Claxton D, Andreeff M, Champlin R, Kavanagh J, Hortobagyi G, Holmes F, Reading C, et al.

J Hematother. 1993 Fall;2(3):373-5.

PMID:
7921999

Supplemental Content

Loading ...
Support Center